IP Library Granted Patent US 9,187,758
Granted Patent B2
US 9,187,758 · App. 12/001,939 · Granted Nov 17, 2015

Optimized non-canonical zinc finger proteins

Inventors: Qihua C. Cai (Westfield, IN); Vipula K. Shukla (Indianapolis, IN); Joseph F. Petolino (Zionsville, IN); Lisa W. Baker (Carmel, IN); Robbi J. Garrison (Fillmore, IN); Ryan C. Blue (Fishers, IN); Jon C. Mitchell (Zionsville, IN); Nicole L. Arnold (Carmel, IN); Sarah E. Worden (Fillmore, IN); Jeffrey Miller (Pleasanton, CA); Fyodor Urnov (Point Richmond, CA)
Assignees: Sangamo BioSciences, Inc.; Dow AgroSciences LLC
C12N15/8243C12N15/8213C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,758
App. No.
12/001,939
Granted
Nov 17, 2015
Kind
B2
Abstract

Disclosed herein are zinc fingers comprising CCHC zinc coordinating residues. Also described are zinc finger proteins and fusion proteins comprising these CCHC zinc fingers as well as polynucleotides encoding these proteins. Methods of using these proteins for gene editing and gene regulation are also described.

Claims (25)

1. A fusion protein comprising:

(a) a cleavage half domain;

(b) a zinc finger protein comprising a non-canonical (non-C2H2) zinc finger, wherein the non-canonical zinc finger has a helical portion involved in DNA binding and wherein at least one zinc finger comprises the sequence Cys-(X A ) 2-4 -Cys-(X B ) 12 -His-(X C ) 3-5 -Cys-(X D ) 1-10 (SEQ ID NO:3), where X A , X B , X C and X D can be any amino acid and wherein

(i) the zinc finger protein is engineered to bind to a target sequence;

(ii) (X D ) 1-10 comprises an amino acid sequence selected from the group consisting of a G residue as the N-terminal residue of (X D ) 1-10 ; QKP; and QLV;

(iii) (X C ) 3-5 comprises N-terminal T, L, A, Q, KE, KK, KQ, KI, KRI, SEGG, SSSN, IKR, IRT, ISS or IRR residues, and

(iv) if (X C ) 3-5 consists of the amino acid residues TKI then the N-terminal residues of (X D ) 1-10 comprise GG, GL or GT; and

(c) a ZC linker interposed between the cleavage half-domain and the zinc finger protein, wherein the ZC linker has the sequence GLRGS (SEQ ID NO:4) or GGLRGS (SEQ ID NO:5).

2. The fusion protein of claim 1 , wherein the region of the zinc finger protein corresponding to His-(X C ) 3-5 -Cys-(X D ) 1-10 consists of one of the amino acid sequences shown in Tables 1, 2, 3, or 4.

3. The fusion protein of claim 1 , wherein X D comprises the sequence QLV or QKP.

4. The fusion protein of claim 3 , wherein the sequence QLV or QKP are the 3 C-terminal amino acid residues of the zinc finger.

5. The fusion protein of claim 1 , wherein (X D ) 1-10 comprises 1, 2 or 3 Gly (G) residues.

6. A fusion protein comprising a zinc finger protein comprising a plurality of zinc fingers, wherein at least one of the zinc fingers comprises a CCHC zinc finger according to claim 1 .

7. The fusion protein of claim 6 , wherein the zinc finger protein comprises 3, 4, 5 or 6 zinc fingers.

8. The fusion protein of claim 6 , wherein finger 2 comprises the CCHC zinc finger.

9. The fusion protein of claim 6 , wherein the C-terminal zinc finger comprises the CCHC finger.

10. The fusion protein of claim 6 , wherein at least two zinc fingers comprise the CCHC zinc finger.

11. The fusion protein of claim 6 , wherein the zinc finger protein comprises any of the sequences shown in Table 8 and is engineered to bind to a target sequence in an IPP2-K gene.

12. A polynucleotide encoding a fusion protein according to claim 1 .

13. A plant cell comprising a fusion protein according to claim 1 .

14. The plant cell of claim 13 , wherein the cell is present in a seed.

15. The plant cell of claim 14 , wherein seed is a corn seed.

16. The plant cell of claim 13 , wherein IPP2-K is partially or fully inactivated.

17. The plant cell of claim 14 , wherein the levels of phytic acid in the seed are reduced.

18. The plant cell of claim 13 , wherein metabolically available levels of phosphorous in the cell are increased.

Assignments (3)
CHANGE OF NAME Recorded Mar 10, 2020
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 052137/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2008
From: MILLER, JEFFREY; URNOV, FYODOR
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 020694/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2008
From: CAI, QIHUA C.; SHUKLA, VIPULA K.; PETOLINO, JOSEPH F.; BAKER, LISA W.; GARRISON, ROBBI J.; BLUE, RYAN C.; MITCHELL, JON C.; ARNOLD, NICOLE L.; WORDEN, SARAH E.
To: DOW AGROSCIENCES, LLC
Reel/Frame 020694/0931 →
Continuity (3)
Provisional Application 60874911 · Dec 14, 2006
Provisional Application 60932497 · May 30, 2007
Related Publication 20080182332A1 · Jul 31, 2008